Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
Sales | 1,111 | 1,338 | 2,754 | 581 | 2,201 |
Cost of Goods | 77 | 78 | 66 | 45 | 132 |
Gross Profit | 1,034 | 1,260 | 2,688 | 536 | 2,069 |
Operating Expenses | 14,388 | 13,153 | 34,167 | 6,304 | 5,063 |
Operating Income | -13,277 | -11,815 | -31,413 | -5,723 | -2,862 |
Other Income | 19 | -1,465 | 7,101 | 64 | 53 |
Pre-tax Income | -13,258 | -13,280 | -24,312 | -5,659 | -2,809 |
Income Tax | 3 | -454 | -2,157 | -25 | 122 |
Net Income Continuous | -13,261 | -12,826 | -22,155 | -5,634 | -2,931 |
Net Income Discontinuous | -198 | -455 | 1,038 | 7,255 | -1,086 |
Net Income | $-13,459 | $-13,281 | $-21,117 | $1,621 | $-4,017 |
EPS Basic Total Ops | -485.91 | -543.07 | -971.82 | 85.75 | -200.08 |
EPS Basic Continuous Ops | -457.33 | -514.49 | -1,028.98 | -257.25 | -142.91 |
EPS Basic Discontinuous Ops | -28.58 | -28.58 | 57.17 | 342.99 | -57.17 |
EPS Diluted Total Ops | -485.91 | -543.07 | -4,859.09 | -1,600.64 | -200.08 |
EPS Diluted Continuous Ops | -457.33 | -514.49 | -5,087.75 | -2,458.13 | -142.91 |
EPS Diluted Discontinuous Ops | -28.58 | -28.58 | 228.66 | 857.49 | -57.17 |
EBITDA(a) | $-12,851 | $-11,389 | $-30,960 | $-5,106 | $-1,732 |